TRACON Pharmaceuticals, Inc. (TCON) Financial Statements (2024 and earlier)

Company Profile

Business Address 4350 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:17,50024,10036,10016,40039,10034,500
Cash and cash equivalents17,43324,07232,13116,41225,13629,467
Short-term investments   3,999 13,9684,999
Other undisclosed cash, cash equivalents, and short-term investments6728(30)(12)(4)34
Other undisclosed current assets7288368148601,5031,557
Total current assets:18,22824,93636,91417,26040,60336,057
Noncurrent Assets
Operating lease, right-of-use asset 1,123   
Property, plant and equipment515016234573
Restricted cash and investments67     
Other undisclosed noncurrent assets 1,571508838  
Total noncurrent assets:1,2411,6215248614573
TOTAL ASSETS:19,46926,55737,43818,12140,64836,130
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,4571,5321,5901,3551,4641,494
Employee-related liabilities1,5321,5901,3551,4641,494
Accrued liabilities1,457     
Debt 11,10710,7536,2352,6041,0842,837
Deferred revenue and credits667
Other undisclosed current liabilities9,8071,3912,7187,87510,9476,800
Total current liabilities:22,37113,67610,54311,83413,49511,798
Noncurrent Liabilities
Long-term debt and lease obligation   1,3912,7395,3434,603
Long-term debt, excluding current maturities   1,3912,7395,3434,603
Liabilities, other than long-term debt9691,1674328503682,742
Deferred revenue and credits2,333
Other liabilities9691,167432850368409
Total noncurrent liabilities:9691,1671,8233,5895,7117,345
Total liabilities:23,34014,84312,36615,42319,20619,143
Equity
Equity, attributable to parent(7,151)11,71425,0722,69821,44216,987
Common stock23191543018
Additional paid in capital229,737219,471204,166165,028161,072121,670
Accumulated deficit(236,911)(207,776)(179,109)(162,334)(139,660)(104,701)
Total equity:(7,151)11,71425,0722,69821,44216,987
Other undisclosed liabilities and equity 3,280     
TOTAL LIABILITIES AND EQUITY:19,46926,55737,43818,12140,64836,130

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues 346  3,0008,755
Revenue, net8,755
Gross profit: 346  3,0008,755
Operating expenses(27,894)(28,693)(16,223)(22,296)(37,740)(26,965)
Operating loss:(27,894)(28,347)(16,223)(22,296)(34,740)(18,210)
Nonoperating income (expense)(1,241)(320)(552)(378)(219)(893)
Other nonoperating income (expense)(247)(2)(7)812(7)
Loss from continuing operations:(29,135)(28,667)(16,775)(22,674)(34,959)(19,103)
Loss before gain (loss) on sale of properties:(28,667)(16,775)(22,674)(34,959)(19,103)
Net loss available to common stockholders, diluted:(29,135)(28,667)(16,775)(22,674)(34,959)(19,103)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(29,135)(28,667)(16,775)(22,674)(34,959)(19,103)
Comprehensive loss, net of tax, attributable to parent:(29,135)(28,667)(16,775)(22,674)(34,959)(19,103)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: